Parkinsonism-hyperpyrexia syndrome after deep brain stimulation surgery: Case report

Neurosurgery

Volumn 66, Issue 5, 2010, Pages

  Kim, Jong Hyun ^a   Kwon, Taek Hyun ^a   Koh, Seong Beom ^a   Park, Jung Youl ^b  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Deep brain stimulation; Hyperpyrexia; Parkinsonism

Indexed keywords

AMANTADINE; CREATINE KINASE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MYOGLOBIN;

AGED; ANAMNESIS; ARTICLE; BRAIN DEPTH STIMULATION; CASE REPORT; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DISEASE DURATION; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERAL ANESTHESIA; HOSPITAL ADMISSION; HUMAN; HYDRATION; HYPERPYREXIA; IDIOPATHIC DISEASE; LABORATORY TEST; LOCAL ANESTHESIA; MICROELECTRODE; NASOGASTRIC TUBE; NAUSEA AND VOMITING; PARKINSON DISEASE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RARE DISEASE; STEREOTAXIC SURGERY; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; FEMALE; FEVER; HUMANS; PARKINSON DISEASE; PARKINSONIAN DISORDERS;

EID: 77951686034     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000367799.38332.43     Document Type: Article

References (21)

1. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003;349(20):1925-1934. (Pubitemid 37409709)
2. Machado A, Rezai AR, Kopell BH, Gross RE, Sharan AD, Benabid AL. Deep brain stimulation for Parkinson's disease: surgical technique and perioperative management. Mov Disord. 2006;21(suppl 14):S247-S258. (Pubitemid 44028285)
3. Factor SA, Santiago A. Parkinsonism-hyperpyrexia syndrome in Parkinson's disease. In: Frucht SJ, Fahn S, eds. Movement Disorder Emergencies: Diagnosis and Treatment. New York, NY: Humana Press; 2005:29-41.
4. Factor SA. Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation. Mov Disord. 2007;22(1):148-149. (Pubitemid 46382692)
5. Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord. 2005;20(3):322-334. (Pubitemid 40613293)
6. Ondo WG, Bronte-Stewart H. The North American survey of placement and adjustment strategies for deep brain stimulation. Stereotact Funct Neurosurg. 2005;83(4):142-147. (Pubitemid 41797951)
7. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J: Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology. 2002;58(3):396-401. (Pubitemid 34150913)
8. Kleiner-Fisman G, Saint-Cyr JA, Miyasaki J, Lozano AM, Lang AE. Subthalamic DBS replaces levodopa in Parkinson's disease. Neurology. 2002;59(8):1293-1294.
9. Calne DB. Treatment of Parkinson's disease. N Engl J Med. 1993;329(14):1021-1027. (Pubitemid 23307912)
10. Granner MA, Wooten GF. Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome. Semin Neurol. 1991;11(3):228-235.
11. Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136-140.
12. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA. 1985;254(19):2792-2795.
13. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41(3):79-83.
14. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10):1137-1145. (Pubitemid 16223648)
15. Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992;31(6):1161-1164.
16. Genís D. Neuroleptic malignant syndrome: impaired dopaminergic systems? Neurology. 1985;35(12):1806.
17. Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology. 1999;52(4):777-781. (Pubitemid 29120184)
18. Linazasoro G, Van Blercom N, Castro A, Dapena MD. Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease. Neurology. 2004;63(3):589-590. (Pubitemid 39031406)
19. Ikebe S, Harada T, Hashimoto T, et al. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord. 2003;9(suppl 1):S47-S49. (Pubitemid 36539393)
20. Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med. 1989;149(9):1927-1931. (Pubitemid 19232210)
21. Arts MP, Nieborg A, Brand R, Peul WC. Serum creatine phosphokinase as an indicator of muscle injury after various spinal and nonspinal surgical procedures. J Neurosurg Spine. 2007;7(3):282-286. (Pubitemid 47480452)